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Abstract
Background: The clinical syndrome of thalassemia intermedia (TI) results from the b-globin genotypes in
combination with factors to produce fetal haemoglobin (HbF) and/or co-inheritance of a-thalassemia. However,
very little is currently known of the molecular basis of Chinese TI patients.
Methods: We systematically analyzed and characterized b-globin genotypes, a-thalassemia determinants, and
known primary genetic modifiers linked to the production of HbF and the aggravation of a/b imbalance in 117
Chinese TI patients. Genotype-phenotype correlations were analyzed based on retrospective clinical observations.
Results: A total of 117 TI patients were divided into two major groups, namely heterozygous b-thalassemia (n =
20) in which 14 were characterized as having a mild TI with the Hb levels of 68-95 g/L except for five co-inherited
aaa
anti-3.7 triplication and one carried a dominant mutation; and b-thalassemia homozygotes or compound
heterozygotes for b-thalassemia and other b-globin defects in which the b
+-thalassemia mutation was the most
common (49/97), hemoglobin E (HbE) variants was second (27/97), and deletional hereditary persistence of fetal
hemoglobin (HPFH) or δb-thalassemia was third (11/97). Two novel mutations, Term CD+32(A!C) and Cap+39
(C!T), have been detected.
Conclusions: Chinese TI patients showed considerable heterogeneity, both phenotypically and genotypically. The
clinical outcomes of our TI patients were mostly explained by the genotypes linked to the b- and a-globin gene
cluster. However, for a group of 14 patients (13 b
0/b
N and 1 b
+/b
N) with known heterozygous mutations of
b-thalassemia and three with homozygous b-thalassemia (b
0/b
0), the existence of other causative genetic
determinants is remaining to be molecularly defined.
Background
b-thalassemia is one of the most common monogenic
disorders in the world. The incidence for this disease is
high in tropical and subtropical areas including southern
China. In southern China, the carrier rate of b-thalasse-
mia is 2.54% in Guangdong [1] and 6.78% in Guangxi
[2] where two provinces were thalassemia occurred
most frequently. The hemoglobin E (HbE) is one of the
common b-thalassemia variants with carrier rates of
0.09-0.13% [1,3], and 0.19-0.21% [[2], unpuplished report
from our laboratory] , respectively, in these two regions.
According to the clinical phenotypes, b-thalassemia can
be divided into three main types: thalassemia major
(TM), thalassemia trait (TT) and thalassemia intermedia
(TI). TM is a severe form that requires transfusions
from infancy for survival, whereas TT is usually asymp-
tomatic. TI is used to indicate a clinical condition of
intermediate gravity between TT and TM, which
encompasses a wide phenotypic spectrum spanning
from mild anemia to more severe anemia and these
patients require only occasional blood transfusions, if
any [4,5].
Corresponding to the phenotypic diversity, the mole-
cular basis of TI is also variable. The major genetic
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globin and expression of g-globin [6,7]. Some genotypic
factors have been reported to affect synthesis of the
g-globin chain, such as the 3’HS1 (+179 C!T) poly-
morphism [8], the (AT)xNy(AT)z motif in the 5’HS2
site [9], and the (AT)x(T)y motif in the -540 region of
the b-globin gene[10]. Variation of rs11886868 (T!C)
in the BCL11A gene has also been shown to correlate
with increased HbF in European TI patients [11]. In
addition, those factors that can moderate globin imbal-
ances indirectly or cause the b-thalassemia-like pheno-
type, such as GATA-1 [12], alpha hemoglobin
stabilizing protein (AHSP) [13,14], and heme-regulated
initiation factor 2 alpha kinase (HRI) [15], are also
thought to contribute to the phenotypic diversity of TI.
Researchers have described molecular characterization
of TI in Iranian [16], Indian [17], Italian [4,18], Israelis
[19] and other populations [20]. However, to date, the
genetic basis of TI in Chinese patients is still poorly
understood [21]. In this study, a comprehensive analysis
of the molecular basis underlying TI was performed in
southern China. Genotypes of b-globin and other
known modifiers linked to a/b imbalance were investi-
gated in 117 patients with b-thalassemia intermedia phe-
notypes. Their clinical, hematological, and molecular
data were analyzed systematically with the aim of creat-
ing a genotype-phenotype correlation. During the analy-
sis, two novel mutations, Term CD+32(A!C) and Cap
+39(C!T ) ,w e r ef o u n d .T h e s et w om u t a t i o n sw e r e
named according to the standard nomenclature rules of
human hemoglobin mutation http://globin.cse.psu.edu/.
Our findings provide genetic insights of TI occurrence
in southern China and are useful in genetic counselling,
treatment and management.
Methods
Subjects
A total of 117 patients from 109 families with TI pheno-
types were recruited for this study and consisted of the
following: 63 males and 54 females, 73 children and 44
adults. 78 patients (66.7%) came from Guangxi, 37
(31.6%) came from Guangdong, and 2 (1.7%) came from
either Guizhou or Zhejiang. Their ethnic backgrounds
were as follows: 71 Han, 45 Zhuang and 1 Miao. We
recruited the TI patients in this study according to pre-
viously described criteria [4,5,20], in whom the classical
clinical diagnosis of TI patients, such as the steady state
Hb level of 60-105 g/L, age at diagnosis over two years
old, and transfusion independence were emphasized for
all our patients. The protocol for this study was
approved by medical ethics committee of Southern
Medical University. Informed consent was obtained
from each individual or parents of individuals younger
than 18 years old.
Hematological analysis and Clinical data collection
Hematological data: complete blood counts and red cell
indices were determined by automated cell counting
(Model Sysmex F-820; Sysmex Co Ltd, Kobe, Japan); the
levels of HbA, A2 and F were analyzed on the Bio-Rad
Variant II HPLC system (HPLC, VARIAN™,B i o - R a d ,
Hercules, CA, USA).
Clinical data: the information about blood transfu-
sions, thalassemia appearance, and age at diagnosis,
hepatosplenomegaly and splenectomy was obtained by
retrospective clinical data.
Molecular analysis
DNA analysis: genomic DNA was extracted from per-
ipheral blood by standard phenol/chloroform methods.
The 11 known b-thalassemia mutations including -29
(A!G), -28 (A!G), CD17 (A!T), b
E (CD26 G!A),
IVS-1-1(G!T), IVS-1-5(G!C), CD27-28(+T), CD41-42
(-CTTT), CD43 (G!T), CD71-72(+A) and IVS-2- 654
(C!T) [1], the two common deletions including Chi-
nese
Gg
+(
Agδb
0)t h a l a s s e m i a[ 2 2 ]a n dS o u t h e a s tA s i a n
hereditary persistence of fetal hemoglobin (SEA-HPFH)
[23], the three common a-thalassemia deletions (–
SEA,
-a
3.7 and -a
4.2) [1], the six non-deletional mutations
(a
cd30,a
cd31 ,a
cd59,a
QS,a
CS,a n da
WS)[ 1 ] ,t h eaaa
anti-3.7
or aaa
anti-4.2 triplication [24,25] and XmnI site -158 of
the
Gg-globin gene [26,27] were analyzed by previously
described methods. Further sequence analysis was
applied on both b
0/b
0and b
+/b
N or b
0/b
N samples, ana-
lyzed targets for the former (b
0/b
0) include both 3’HS1
and 5’HS2 core region, the promoters of the
Gg-a n d
Ag-globin genes, the (AT)x(T)y sequence variations at
the position -540 of the b-globin gene, a single-nucleo-
tide polymorphism (SNP) of rs11886868 in the BCL11A
gene, as well as the whole a2- and a1-globin genes; and
those for the latter (b
+/b
N or b
0/b
N) include the core
regions of both 5’HS2 and 5’HS3, the whole b-globin
gene and AHSP gene, and the full-lenghth cDNA of
GATA-1 generated by RT-PCR from mRNA. Since HRI
has been shown to modify the phenotypic severity of
b-thalassemia in murine models, we also sequenced the
HRI cDNA in b
+/b
N or b
0/b
N samples by RT-PCR. The
PCR primers used in this study were previously pub-
lished [1,8,9,28] or designed by us as listed in table 1.
Each of the above polymorphic loci with repeat motifs
in heterozygous individuals was verified by sequencing
cloned PCR products.
RNA analysis
Total cellular RNA was isolated from fresh peripheral
blood using QIAamp RNA Blood Mini Kit (Qiagen,
Germany). The cDNA synthesis was performed using
the ExScript RT reagent Kit (TaKaRa Biotechnology,
China). The expression levels of b-globin (target gene)
and b-actin (control gene) were measured by SYBR
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described previously by Yipeng [28]. Five heterozygous
subjects carrying the Cap+39(C!T) mutation and three
heterozygous subjects carrying the Term CD+32(A!C)
mutation were selected respectively, as two patient
groups, while six normal subjects were used as the con-
trol group.
b-globin haplotype analysis: the b-globin haplotypes
associated with the two novel mutations were analyzed
with PCR amplification followed by restriction-enzyme
digestion [28]. Seven classical polymorphic restriction
enzyme sites selected for haplotype analysis were Hinc
II-5’ε,H i n dI I I -
Gg,H i n dI I I -
Ag,H i n c I I - ψb, Hinc II-3’ψb,
Ava II-b and Bam HI-3’b. Each individual was scored
for the presence (+) or absence (-) of each of the seven
RFLP sites.
Statistical methods
Statistical analysis was performed using SPSS software
( V e r s i o n1 3 . 0 ,S P S Si n c ,U S A ) .T h ed i f f e r e n c eo ft h e
relative mean mRNA concentration between mutation
carriers and normal individuals were analyzed by the
independent samples t-test. A p-value < 0.05 was con-
sidered as statistically significant.
Results
Molecular basis of 117 TI patients in southern China
In this study, 117 Chinese individuals between 2 and 60
years of age were enrolled to characterize the molecular
basis of b-thalassemia intermedia in southern China.
Their clinical, hematological and molecular data are
summarized in table 2. According to their genotype of
b-globin, we divided them into two major types: Type I
b-thalassemia homozygotes or compound heterozygotes
for b-thalassemia and other b-globin defects (Hb E,
HPFH or δb-thalassemia) (n = 97) who inherited two
deficient b-globin alleles and Type II b-thalassemia het-
erozygotes (n = 20) who had only a single b-thalassemia
allele. Statistical comparison showed that their steady-
state Hb level of Type II (86.7 ± 10.8 g/L) was signifi-
cantly higher than that of Type I (75.7 ± 11.4 g/L)
(Mann-Whitney test, p < 0.05). In contrast, their HbF
level of Type I (57.9 ± 27.2%) was much higher than
that of Type II (4.0 ± 3.8%, p = 0.000). Significant differ-
ences in hematological parameters such as MCV (66.3 ±
8 . 7f Li nT y p eIv s .5 8 . 7±6 . 9f Li nT y p eI I ,p = 0.004)
and MCH (20.2 ± 2.5 pg in Type I vs. 18.5 ± 2.0 pg in
Type II, p = 0.000) were also observed. In total, we
detected 18 b-thalassemia alterations including two
novel ones which were termed as Term CD +32(A!C)
and Cap+39(C!T), b-globin variant HbE, the two dele-
tional mutations which can lead to SEA-HPFH or (δb)
0-
thalassemia Chinese
Gg
+(
Agδb)
0 (table 3).
Type I b-thalassemia homozygotes or compound het-
erozygotes for b-thalassemia and other b-globin defects
were detected in 97 TI patients (82.9%) as follows: (i)
Fifty-nine (50.4%) had homozygous or compound het-
erozygous b-thalassemia alleles with co-existing normal
(44 cases, 37.6%) or mutant (15 cases, 12.8%) a-globin
genes. Four types of the a-thalassemia alterations were
identified in our TI patients, including the -a
3.7,- a
4.2,
–
SEA alleles or a
CSa. We observed two TI patients with
particular combinations of a-globin defects and com-
mon b-globin genotypes. One was caused by co-exis-
tence of Hb H disease (–
SEA/-a
4.2)a n db-thalassemia
compound heterozygosity CD17 (A!T)/IVS-2-654
(C!T), while the other was caused by aa/aaa
anti-3.7
and b-thalassemia homozygosity of the -28 (A!G)
Table 1 Primer sequences and their location
Primer Sequence(5’!3’) GenBank No. Location Nucleotide(nt) Product length
b-540 FP: tttcccaaaacctaataagtaac
RP: aacttcatccacgttcacc
NG_000007
NG_000007
nt69848-nt69870
nt70647-nt70665
818 bp
Gg-promoter FP:tgaaactgttgctttatagga t
RP: gagcttattgataacctcagacg
NG_000007
NG_000007
nt42215-nt42236
nt42850-nt42872
657 bp
Ag-promoter FP:ctgctaactgaagagactaagatt
RP: caaatcctgagaagcgacct
NG_000007
NG_000007
nt47259-nt47283
nt47962-nt47981
723 bp
a2-globin gene FP:tggagggtggagacgtcctg
RP: ccattgttggcacattccgg
NG_000006
NG_000006
nt33537-nt33556
nt34062-nt34621
1085 bp
a1-globin gene FP:tggagggtggagacgtcctg
RP:tccatcccctcctcccgcccctgccttttc
NG_000006
NG_000006
nt37341-37360
nt38492-38521
1180 bp
BCL11A FP: tgaggagacccaaacagttaaag
RP: aacccacatggcaaccaatag
NT_022184
NT_022184
nt49880-nt49902
nt50359-nt50379
500 bp
AHSP FP:tgtcatgtaatagggctcagtaa
RP:tggtcactcaaggctgctaac
NW_001838236.1
NW_001838236.1
nt1217371-nt1217395
nt1218685-nt1218705
1335 bp
HRI FP: accccgaatatgacgaatc
RP: aaggcttactaaatacaacg
NM_014413
NM_014413
nt166-nt184
nt2034-nt2053
1888 bp
GATA-1 FP: tgggatcacactgagcttgc
RP: gctacaagaggagaaggacacc
NM_002049
NM_002049
nt10-nt29
nt1365-nt1387
1378 bp
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Page 4 of 10mutations. The first case was a male child with Hb 66 g/
L and a splenectomy, when he was diagnosed at the age
of 3 years, he had been received a transfusion only one
time. His blood indices showed RBC 4.13×10
12/L,
MCV51.7fL, MCH16.0 pg, HbA2 4.0%, and HbF38.1%.
The second case was a 12-year-old boy who had never
been transfused. Pallor, hepatosplenomegaly and slight
facial alterations were noted. He had presence of blood
indices with microcytic-hypochromic anemia: Hb76 g/L,
MCV76.2fL, MCH27.3 pg, HbA2 3.4% and HbF65.2%.
(ii) Twenty-seven (23.1%) were HbE/b
0 compound het-
erozygotes. No HbE/b
+ heterozygote or co-incident
a-globin mutations were found in this group. (iii) Eleven
(9.4%) carried SEA-HPFH (7 cases) or Chinese
Gg
+(
Agδb)
0 (4 cases) deletions in addition to having one b-thalas-
semia mutation. Among them, two were IVS-2-654
(C!T)/Chinese
Gg
+(
Agδb)
0 and -28 (A!G)/Chinese
Gg
+(
Agδb)
0, respectively, both plus one –
SEA deletion,
which were first reported by Li in our lab [22].
Type II b-thalassemia heterozygosity was detected in
20 TI patients (17.1%) as follows: (i) Fourteen (12.0%)
carried a single b-thalassemia allele and normal a-globin
genes. (ii) Five (4.2%) had a single b-thalassemia allele
and co-inherited aaa
anti-3.7 triplication. No aaa
anti-4.2
triplication was detected. (iii) One patient (0.9%), in a
Miao family, was a heterozygote for a frameshift b-tha-
lassemia mutation at CD 53 (-T). This mutation is con-
sidered to be a dominant form and was first reported by
Yi in our lab in 2008[28].
Analysis of genotypic modifiers in 3 b
0/b
0 and
10 b
0/b
N or b
+/b
N TI cases
Usually, thalassemia patients with b
0/b
0 genotype and
normal a- g l o b i ng e n eh a dt h eT Mp h e n o t y p e s ,b u tw e
detected 3 b
0/b
0 patients with TI phenotypes whose Hb
levels are 74-99 g/L (table 4). We examined the exis-
tence of known genetic modifiers, which related to
increasing HbF levels in these three cases. The clinical,
hematological and molecular results observed from the
group of patients are listed in table 4.
Fourteen patients who displayed the relative mild TI
phenotypes with steady Hb levels of 68-95 g/L were
identified to be heterozygotes with one known common
mutation for b-thalassemia and normal a-globin gene.
Analysis of other known genetic modifiers that mainly
focused on several factors of aggravate a/b imbalance
were done in ten patients (blood samples from other
four patients were not available). The overall findings
are summarized in table 5.
Two novel mutations of the b-globin gene
Two novel mutations, Term CD+32(A!C) (GenBank
No: FJ876836) and Cap+39(C!T) (GenBank No:
FJ876835), were identified in this study (Figure 1).
Family A: Term CD+32(A!C). The proband (AIII1)
displayed the TI phenotypes with Hb 72 g/L, HbA2 4.6%
and HbF 64.8%. His father was found to have a CD 27-28
(+C) mutation, whereas his mother was found to have a
novel mutation of an A!C substitution at nucleotide
position +32 from the stop codon TAA in the 3’ UTR
region of the human b-globin gene (Figure 1A). The pro-
band was a compound heterozygote of Term CD+32
(A!C)/CD 27-28(+C) with XmnI (+/+) homozygosity.
The haplotypes associated with Term CD+32(A!C) and
CD 27-28(+C) are “–+++-+"and “–++++-”, respectively.
Family B: Cap+39(C!T). The proband (BIII1) showed
a mild TI phenotypes with Hb 105 g/L, MCV 53.7 fL,
MCH 17.4 pg, HbA2 5.8%. His father had a novel muta-
tion of a C!T substitution at nucleotide position +39
from the cap site in the 5’ UTR region of the human
b-globin gene. This mutation was likely inherited from
his dead grandfather. His mother did not provide her
blood sample, but she was an obligate carrier with CD
41-42(-CTTT) mutation since her son (BIII1) was a
compound heterozygote of Cap+39(C!T)/CD 41-42
(-CTTT) with Xmn I (-/-) homozygosity. Interestingly,
his father (BII3) and four other family members (BII1,
BII2, BII4, and BIII2) were all heterozygotes of Cap+39
(C!T) mutations. Since they do not have any evident
Table 3 b globin mutations identified in 117 patients
with TI phenotype
Mutation Type of
thal
Location No. of Chr. Total (%)
Type
I
Type
II
-28 (A!G) b
+ 5’UTR 42 1 43(20.1%)
CD 41-42(-CTTT) b
0 Exon 39 3 42(19.6%)
CD 17 (A!T) b
0 Exon 29 5 34(15.9%)
CD 26 (G!A) Hb E Exon 27 0 27(12.6%)
IVS-2-654 (C!T) b
0 Intron 12 8 20(9.3%)
IVS-2-5 (G!C) b
+ Intron 11 0 11(5.1%)
CD 71/72 (+A) b
0 Exon 6 2 8(3.7%)
SEA-HPFH HPFH 7 0 7(3.3%)
IVS-1-1 (G!T) b
0 Intron 5 0 5(2. 3%)
-29(A!G) b
+ 5’UTR 5 0 5(2.3%)
Chinese
Gg
+(
Agδb)
0 δb thal 4 0 4(1.9%)
CD 43 (G!T) b
0 Exon 2 0 2(0.9%)
-73(A!T) b
+ 5’UTR 1 0 1(0.5%)
Term CD +32
(A!C)
1
b
+ 3’UTR 1 0 1(0.5%)
Cap+39 (C!T)
2 b
++ 5’UTR 1 0 1(0.5%)
CD 15/16 (+G) b
0 Exon 1 0 1(0.5%)
CD 27/28(+C) b
0 Exon 1 0 1(0.5%)
CD 53(-T) b
dominant Exon 0 1 1(0.5%)
Total number of chromosomes 194 20 214(100%)
1,2 Novel mutations found in this study.
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Page 5 of 10hematologic phenotype, we regard this mutation as b
++
(silent b-thalassemia).
Sequence alignment showed that Term CD+32(A) and
Cap+39(C) were conserved sites during evolution (Fig-
ure.1). In addition, we randomly choosed 156 cases nor-
mal individuals from Guangxi as control samples and
excluded the possibility of that the two new mutations
were polymorphic sites. These control samples are 13-
19 years old with Hb (130-152 g/L), MCV (83-100 fL),
MCH (28-33.8 pg), HbA (96.54-97.94%) and HbA2
(2.06-3.46%).
R e a l - t i m eP C Rw a su s e dt oa n a l y z et h em R N Al e v e l .
Two standard curves were generated: y =- 3 . 6 7 2 x + 19.787
(R
2 =0 . 9 9 9 )f o rb-globin mRNA and y = -3.466x+24.000
(R
2 = 0.999) for b-actin mRNA. The mean relative mRNA
concentrations were 0.835 ± 0.048 (n =3 )f o rt h eT e r m
CD+32(A!C) group, 1.093 ± 0.118 (n =5 )f o rt h eC a p
+39(C!T) group, and 1.016 ± 0.098 (n =6 )f o rt h e
Table 4 Hematological data and existence of genetic modifiers identified among 3 b
0/b
0 TI patients
Studied items Data of patients
123
Age/Age at diagnosis (years) 7/2 5/3 19/12
Age of 1
st Transfusion (years)/frequency 4/1 time every 7 months 4/1 time every 6 months 17/only 1 time
Hepatosplenomegaly
1 mild 2/2(cm) 0.5/8(cm)
RBC (10
12/L) 3.64 3.51 5.32
Hb (g/L) 74 81 99
MCV (fL) 70 77 59
MCH (pg) 20.3 23.0 18.6
MCHC (g/L) 289 298 313
HbF (%) 96.4 59.0 97.3
HbA2 (%) 2.1 2.7 2.7
b-globin genotype
1 CD 17 (A!T)/IVS-2-654 (C!T) IVS-1-1 (G!T)/CD 41-42 (-CTTT) CD 17(A!T)/CD17 (A!T)
Xmn I +/- +/- -/-
b-540 (AT)7(T)5/(AT)8(T)5 (AT)7(T)7/(AT)8(T)5 (AT)7(T)5/(AT)7(T)5
5’ HS2 (AT)9(N)12(AT)10/(AT)8(N)12(AT)10 (AT)9(N)12(AT)10/(AT)8(N)12(AT)10 (AT)9(N)12(AT)11/(AT)8(N)12(AT)11
1 numbers before or after the slash indicate the enlarged liver or spleen in size (cm: centimeter) when first diagnosis. The a-globin genotype, the sequence
analysis of Ag-(-500~+223) and Gg-(-618~+39) globin genes are all normal in the three samples. The genotypes of both 3’HS1(+179) polymorphic site and
rs11886868 SNP site of BCL11A gene are all C/C in the three samples.
Table 5 Htological data and existence of genetic modifiers identified among 10 b
+/b
N or b
0/b
N TI patients
Studied items Data of patients
12345 6789 1 0
Age/Age at diagnosis
(years)
26/10 17/5 7/7 5/4 26/8 7/7 5/5 12/12 6/3 38/20
Transfusion No No No No Occasionally No No No No No
Hepatosplenomegaly
1 No No No No 0.5/6(cm) No mild No No No
RBC (10
12/L) 4.05 5.83 5.16 5.52 3.33 5.37 5.75 5.77 5.03 4.57
Hb (g/L) 89 88 91 88 68 94 95 84 82 92
MCV (fL) 64 49 50 51 68 53 54 60 54 57
MCH (pg) 21.9 15.0 17.6 15.9 20.4 17.5 16.5 19.1 16.3 20.1
MCHC (g/L) 342 307 350 314 298 328 305 319 302 355
HbF (%) 2.1 6.2 2.6 2.2 8.1 1.3 4.3 0 1.5 2.5
HbA2 (%) 5.5 4.3 5.2 5.8 2.6 5.6 5.1 5.8 5.5 5.2
b-globin genotype -28
(A!G)/N
CD 17
(A!T)/N
CD 17
(A!T)/N
CD 17
(A!T)/N
IVS-2-654
(C!T)/N
IVS-2-654
(C!T)/N
CD41-42
(-CTTT)/N
IVS-2-654
(C!T)/N
CD71-72
(+A)/N
CD71-72
(+A)/N
Xmn I -/- +/- -/- -/- -/- -/- -/- -/- -/- -/-
GATA-1 Normal Normal Normal Normal Normal Normal ND ND ND ND
HRI
2 (T/T) (T/T) (T/C) (T/T) (T/C) (T/C) (T/C) (T/T) (T/C) (T/T) (C/C) (C/C) ND ND ND ND
1 numbers before or after the slash indicate the enlarged liver or spleen in size (cm: centimeter) when first diagnosis.
2 Genotypes of two SNP sites including
rs2639 and rs2640 detected in the HRI cDNA. ND: not determined,because of no mRNA available for these samples. The a-globin genotype, analysis of core
regions of both 5’HS2 and 5’HS3, and AHSP gene are all normal in the tested ten samples. Blood samples from other four out of fourteen TI patients with
heterozygous genotypes were not available, thus the later three targets in the table can not be conducted for these four patients.
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Page 6 of 10normal control group after a normalization procedure
using linear regression equations. Statistical analysis
showed that there was a significant difference (p = 0.021)
of mean relative b-globin mRNA concentration between
the Term CD+32(A!C) group and the control group.
The decreased level of b-globin mRNA in the patient
group compared with that of the normal control group
was calculated to be 17.8%. In contrast, no significant dif-
ference (p = 0.270) was found between the Cap+39(C!T)
group and the control group.
Discussion
Provision of appropriate treatment and management for
TI patients is still a challenge because its characteristic
features, phenotypic diversity, and genotypic heterogene-
ity, the clinical severity of thalassemia intermedia cases
are very difficult to predict from their genotypic data.
The molecular mechanisms underlying different popula-
tions in Europe [18,20], Israel [19], India [17] and Iran
[16] had been reported. However, the molecular basis of
Chinese TI patients was still uncertain, which brought
about much trouble for Chinese doctors in offering
genetic counselling, treatment and management. The
present phenotype-genotype correlation data observed
from 117 Chinese TI patients could provide solid basis
for improving the understanding this problem (table 2).
On the basis of the clinical pictures and statistical
results of hematological parameters, type I patients were
more clinically severe than type II patients. This is a
patient-based study in which the in-patient samples
were recruited during the period of about 2 years from
Guangxi and Guangdong Provinces, where the thalasse-
mia are most endemic in southern China. We believe
that the molecular basis of TI obtained from this study
should be generalizable to the Chinese TI patients of
the various regions in southern China because the dif-
ferences between regions in southern China for the
ß-thalassemia mutation spectrum in the southern Chi-
nese are not statistically significant according to pre-
viously observations [1-3,5]. However, there were some
milder forms of TI patient’s samples who were out-
patient we might have missed and most of heterozygotes
Figure 1 Identification of two novel mutations showing the (A)Term CD+32(A-C) and the (B) Cap+39(C-T). The hematological data and
a/b globin genotype of two family members are listed in tables. The probands are labeled by the arrow in the family pedigrees. DNA
sequences of sense strand are also shown, downward arrows indicating the mutation nucleotides (overlapping peaks are indicated by N). The
alignment of b-globin sequences are shown on the bottom. (EMBL accession No.: chimpanzee ENSPTRT00000006177, human ENST00000335295,
horse ENSECAT00000010442, monkey ENSMMUT00000006876, mouse ENSMUST00000098192, and zebrafish ENSDART00000101713). *(Blood
samples not avaiable). T+32: Term CD+32(A-C), 27-28:CD 27-28(+C), +39:Cap+39(C-T), and 41-42: CD 41-42 (-CTTT).
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Page 7 of 10(10/14) whose negative results could not be explained
were detected in Guangxi, two limitations of our study
should be noted: (1) Maybe there was a broad spectrum
of genetic defects in the Chinese TI patients, such as no
the HbE/b
+ TI patients could be identified in our
cohort. (2) The finding of heterozygotes with TI pheno-
type might not provide representitive profile in the Chi-
nese population.
According to our molecular analysis, three main char-
acteristic features of Chinese TI patients were found.
First, the homozygous or compound heterozygous forms
with minor b-thalassemia mutations (the b
+-thalassemia
alleles) were a common pathogenetic mechanism of dis-
ease in Chinese TI patients, in which 49 out of 59
patients was found to having b-globin genotypes of b
+/b
+ (11 cases) and b
+/b
0 (38 cases), among them 41 with
co-existing normal a-globin genes and 8 with mutant a-
globin allele (table 2). In other words, the b
+-thalassemia
mutation is a major contribution of genes to the Chi-
nese TI patients. In addition to this, additional an a-tha-
lassemia defects may reduce the severity of homozygous
b-thalassemia. We observed 14 such cases (23.7%, 14/
59) with co-inheritance of b-thalassemia (b
+/b
+ or b
+/b
0)a n da-thalassemia defects in the patient group.
Second, the affect of an XmnI polymorphism in increas-
ing HbF levels was not as important as it was in other
populations. The ratio of XmnI [(+/+), (+/-), (-/-) and
(NA, not available)] pattern was detected to be
[1:30:75:11] in 117 cases, while the same ratio in 52 Ira-
nian TI patients was [20:20:10:2] [16]. In India, among
73 TI patients, 20 of them (27.4%) were confirmed to be
homozygous for the XmnI polymorphism [17]. Third,
the molecular mechanism of more than half of the tha-
lassemia heterozygote cases (14/20) was unexplained.
Twenty individuals carried only one b-thalassemia allele:
one (5%) was dominantly inherited; five (25%) had co-
inherited triplicated a-globin genes; and 14 (70%) had
normal a- g l o b i ng e n e s .I nc o n t r a s t ,t h ea-globin gene
triplication was determined to be the predominant fac-
tor of Indian heterozygous thalassemia patients (14/23
cases) [17]. In Ho’s research, among 22 heterozygous
b-thalassemia intermedia cases, 10 patients had a tripli-
c a t i o n[ 2 0 ] .F u r t h e r m o r e ,n oH b E / b
+ heterozygote was
observed in our cases while 9/45 TI patients were HbE/
b
+ heterozygotes in Thailand [29], suggesting that HbE/
b
+ heterozygosity perhaps displayed a more milder form
of TI in Chinese people, which would help doctors in
providing appropriate genetic counselling. HbE/b-thalas-
semia results in a varied clinical expression ranging
from severe transfusion dependence to a complete lack
of symptoms [29,30]. In this study, there are 27 cases
HbE/b
0 TI patients whose clinical phenotypes including
Hb levels, transfusion, splenectomy, age at diagnosis,
and so on, varies greatly (table 2). It is very difficult to
predict the clinical phenotype of the HbE/b-thalassemia
although it was reported that a system for classifying
disease severity of HbE/b-thalassemia had been con-
structed [29,31]. The possible genetic mechanisms for
phenotypic diversity of HbE/bthalassemia have been
analyzed in some literatures [29,30,32]. We also found
two patients that were compounds of b-thalassemia, δb-
thalassemia and a-thalassemia genes. This was rarely
reported in other ethnicities.
Three b
0/b
0 TI patients with normal a-globin gene
remained unexplained despite extensive effort to exam-
ine the existence of known genetic modifiers linked to
increase HbF levels (table 4). The non-deletional forms
of HPFH were excluded in sequencing the promoter
region of the
Gg-a n d
Ag-globin genes. Two cases were
+/- of XmnI, which partially, but not completely
explains the high level of HbF. The 3’HS1 (+179 C!T)
and rs11886868 (T!C) variations were shown to corre-
late with increased HbF in European TI patients [8,11].
The three patients all had C/C genotypes of both at
+179 of 3’HS1 and rs11886868. However, we could not
consider that C/C genotypes of rs11886868 contributed
to the high HbF level based on two facts. One is that
the frequency of C/C genotypes was 0.867 in Chinese
people from the HapMap data http://www.hapmap.org/.
The second is that an additional 115 samples were ana-
lyzed, including 30 TI patients (25 b
0/b
+,5b
+/b
+)a n d
85 normal individuals, in which all were found to be the
C/C genotype (data not shown). The (AT)8N12(AT)11
motif in the 5’H S 2s i t ea n dt h e( A T ) 9(T)5 motif in the
-540 region had been previously found to be associated
with elevated HbF [9,10], but we did not find them in
the 3 cases.
We found 14 patients with heterozygous for b-thalas-
semia among our 117 TI patient cohort, in whom the b-
globin gene was found to be structurally intact by
sequence analysis and the second a-globin gene triplica-
tion was excluded. They mostly manifested a relatively
mild form of TI because of the Hb levels being 68-95 g/
L, the average age at diagnosis being 7.5 ± 5.1 (years),
no blood transfusion or occasionally received (1/14) and
mild hepatosplenomegaly (5/14). As for the underlying
defective targets, we focused on primary genetic modi-
fiers that could modulate the imbalance of a/b for
investigation in ten TI patients (table 5). We evaluated
the effects of some potential modifiers involving one
linked to the b-globin gene cluster, the LCR resides in
the 5’HS2 and 5’HS3 regions [33], and three ones not to
be linked to the b-globin cluster, AHSP [14], GATA-1
[12] and HRI. The later is a kinase that can be inacti-
vated by hemin, which is very recently reported to mod-
ify the phenotypic severity of murine models of
erythropoietic protoporphyria and b-thalassemia [15].
Sequence analysis of the core regions of 5’HS2 and
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possibility that mutations in these control regions redu-
cing the expression of b-globin gene. No mutations in
the cDNA sequences of both AHSP and GATA-1 have
been found. In the case of HRI, the polymorphism of
rs2639 and rs2640 were detected. The rs2639 (A!G) is
a synonymous mutation and the rs2640 (A!G) is a
missense mutation resulting in a K558R substitution.
However, the affect on the function of this substitution
is unknown since Lys (K) and Arg (R) are similar in
amino acid properties. These results indicate the exis-
tence of causative genetic determinants have not been
defined molecularly, in agreement with the similar con-
clusion from Rosatelli’s experiment [34] although there
were a few differences between the candidate targets for
these two studies.
In this study, we reported two novel mutations in the
UTR regions of the human b-globin gene (Figure.1).
The Term CD+32(A!C) mutation slightly reduced b-
globin mRNA levels to 17.8% less than the normal level.
The reduced b-globin mRNA levels were not detected
in the individuals with Cap+39(C!T) mutation. The
detailed mechanisms of two novel mutations are not
clear at present. Functional experiments, such as analy-
sis of mRNA stability and trafficking in erythrocytic
cells should be performed in the future.
Conclusions
Chinese TI patients showed a high degree of heteroge-
neity in both phenotypic and genotypic aspects. Some
cases could not be explained according to the present
data. A more detailed analysis of genetic modifiers mod-
ulating the imbalance of a/b will provide more insight
into the recognition of thalassemia intermedia. More-
over, other potential genetic determinants which have
been demonstrated in cancers and single gene disorders
including a-a n db-thalassemia, such as a gain-of-func-
tion regulatory SNP in a nongenic region [35], loss of
heterozygosity in the b-globin gene [36], segmental
duplications involving the a-globin gene cluster [37],
uniparental disomy event[38], DNA methylation and
chromatin alterations, should also be considered.
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